Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung.
CONCLUSIONS: Detection of ALK expression by IHC is reliable and the most practical way of identifying NSCLC patients likely to benefit from crizotinib treatment.
PMID: 28705139 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
More News: Adenocarcinoma | Biomedical Science | Cancer | Cancer & Oncology | Fish | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Science | Smokers | UK Health